Foster Victor Wealth Advisors LLC lifted its holdings in STERIS plc (NYSE:STE – Free Report) by 2.8% in the third quarter, HoldingsChannel.com reports. The fund owned 92,031 shares of the medical equipment provider’s stock after buying an additional 2,503 shares during the quarter. STERIS comprises 0.9% of Foster Victor Wealth Advisors LLC’s portfolio, making the stock its 28th biggest holding. Foster Victor Wealth Advisors LLC’s holdings in STERIS were worth $20,428,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in STE. Western Wealth Management LLC bought a new stake in STERIS during the 1st quarter valued at approximately $25,000. Elevation Wealth Partners LLC boosted its stake in STERIS by 1,130.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 113 shares during the period. Meramec Financial Planners LLC purchased a new stake in STERIS during the 1st quarter valued at approximately $33,000. Trust Co. of Vermont purchased a new stake in STERIS during the 2nd quarter valued at approximately $41,000. Finally, Community Financial Services Group LLC raised its position in shares of STERIS by 50.0% during the third quarter. Community Financial Services Group LLC now owns 216 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 72 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.
Insider Buying and Selling at STERIS
In related news, Director Mohsen Sohi sold 4,058 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total value of $956,795.24. Following the sale, the director owned 24,305 shares in the company, valued at approximately $5,730,632.90. The trade was a 14.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.12% of the company’s stock.
STERIS Price Performance
Shares of STERIS stock opened at $221.12 on Thursday. The firm has a market cap of $21.56 billion, a PE ratio of 27.03 and a beta of 0.92. The stock has a 50 day moving average of $220.17 and a 200 day moving average of $217.96. The company has a current ratio of 1.91, a quick ratio of 1.35 and a debt-to-equity ratio of 0.23. STERIS plc has a 12 month low of $195.14 and a 12 month high of $269.44.
STERIS (NYSE:STE – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.10. The business had revenue of $1.49 billion for the quarter, compared to the consensus estimate of $1.49 billion. STERIS had a return on equity of 14.34% and a net margin of 13.34%. The company’s revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.34 EPS. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. On average, research analysts expect that STERIS plc will post 11.12 EPS for the current fiscal year.
STERIS Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, September 25th. Investors of record on Friday, September 4th were issued a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.2%. This is a boost from STERIS’s previous quarterly dividend of $0.63. The ex-dividend date of this dividend was Friday, September 4th. STERIS’s payout ratio is 33.74%.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on STE shares. Piper Sandler reissued an “overweight” rating and issued a $275.00 target price (up from $270.00) on shares of STERIS in a report on Friday, August 7th. UBS Group cut their target price on shares of STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of STERIS in a report on Monday, August 24th. Finally, Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, October 11th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and a consensus price target of $271.33.
Check Out Our Latest Research Report on STERIS
STERIS Company Profile
STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, procedural care and the safe manufacture of healthcare and life sciences products. Its offerings include surgical equipment and operating-room solutions, sterilization and decontamination systems, endoscopy products, cleaning and disinfection technologies, and related consumable products.
The company also provides outsourced sterilization and laboratory services through its Applied Sterilization Technologies business.
Featured Articles
- Five stocks we like better than STERIS
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
